[1] 倪童天,陆伦根. 慢性乙型肝炎肝纤维化临床诊断和治疗进展.实用肝脏病杂志,2010,13(2):142-145. [2] 苗雅娇,赵守松. 40例慢性乙型肝炎轻度患者肝组织病理学变化研究. 实用肝脏病杂志,2012,15(1):7-9. [3] 庄辉. 2012年版欧洲肝病学会慢性乙型肝炎病毒感染管理临床应用指南更新要点. 中华传染病杂志,2012,20(6):427-429. [4] Lok AS,McMahon BJ. Chronic hepatitis B. Hepatology,2007,45(2):507-539. [5] Vergniol J,Boursier J,Coutzac C,et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology,2014,60(1):65-76. [6] 中华医学会肝病学分会和感染病学会分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [7] Scheuer PJ. The nomensclature of chronic hepatitis:time for a change. J Hepatol,1995,22(1):112-114. [8] Castera L. Noninvasive methods to assess liver disease in patientswith hepatitis B or C. Gastroenterology,2012,142:1293-1302,e4. [9] Marcellin P,Lada O,Asselah T. Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine.Hepatol Res,2007,37(s1):S55-S61. [10] Sonneveld MJ,Rijckborst V,Boucher CA,et al. Prediction of sustained response to peg-interferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology,2010,52(4):1251-1257. [11] Chan HL,ThompsonA,Martinot-Peignoux M,et al. Hepatitis B surface antigen quantification:why and how to use it in 2011-acore group report. J Hepatol,2011,55(5):1121-1131. [12] Chou YC,Yu MW,Wu CF,et a1. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma,Gut,2008,57(1):91-97. [13] Zheng RD,Xu CR,Jiang L,et a1. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis.Int J Med Sci,2010,11,7(5):272-277. [14] Petta S,Macaluso FS,Barcellona MR,et a1. Serum γ-glutamyltransferase levels,insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One,2012,7(12):e51165. [15] Nguyen MH,Trinh H,Garcia RT,et a1. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation. Hepatology,2005,42(4 Suppl 1):593A. [16] Vergniol J,Foucher J,Castera L,et a1. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat,2009.16(2):132-140. [17] Xun YH,Zang GQ,Guo JC,et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol,2013,28(11),1746-1755. [18] Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol,2014,20(3):228-236. [19] Zheng RD,Chen JN,Zhuang QY,et a1. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis.Int J Med Sci,2013,10(5):641-646. [20] Liao B,Wang Z,Lin S,et al. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One,2013,8(10):e78672. [21] Papatheodoridis GV,Manolakopoulos S,Liaw YF,et a1. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT:a systematic review. J Hepatol,2012,57(1):196-202. [22] Chen YC,Huang SF,Chu CM,et a1. Serial HBV DNA levels in patients with ersistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat,2012,19(2):138-146. |